Auxilium Pharmaceuticals — Merger or Acquisition (October 2014)
10 slides from Auxilium Pharmaceuticals's merger presentation, Oct 10, 2014
Slide 1: Rule 425 filing legend
Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slide
Slide 2: Endo Town Hall Fall 2014
Endo Town Hall Fall 2014 Rajiv De Silva President and Chief Executive Officer ©2014 Endo Pharmaceuticals Inc. All rights reserved.
Slide 3: Additional Information
Additional Information ADDITIONAL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc
Slide 4: Forward-Looking Statements
Forward-Looking Statements This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regardingthe proposed tran
Slide 5: Our Journey to Date
Our Journey to Date Restructured for efficiency and strengthened the organization Increased focus on core businesses to maximize organic growth potential Divested HealthTronics due to limited fit with company strategy Transformational transaction with Paladin Labs resulting in re-domicile to Ireland
Slide 6: The Next Step: A Compelling Combination
The Next Step: A Compelling Combination Aligns with Endo’s strategy of pursuing accretive, value creating growth opportunities Enhances Endo's branded pharmaceutical business with the addition of Auxilium's leading men's healthcare products and development portfolio Accelerates growth of and maximiz
Slide 7: Auxilium Snapshot
Auxilium Snapshot Ticker: NASDAQ “AUXL” Headquarters: Chesterbrook, Pennsylvania Founded: 1999 Headcount: ~480 employees Specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences Emerging leader in men's healthcare and has strateg
Slide 8: Combination Aligns with Endo's Strategic Direction
Combination Aligns with Endo’s Strategic Direction Endo executing strategic plan to enhance shareholder value Meeting or exceeding financial targets Maximizing the growth potential of core businesses Continued investment in de-risked R&D Lean and efficient operating model Pursuing accretive value cr
Slide 9: Accelerating Organic Growth
Accelerating Organic Growth Auxilium’s FDA-approved products in urology, orthopedics, and other areas are natural complements to men’s health and pain products in Endo’s branded pharmaceuticals portfolio Endo expects to optimize Auxilium’s portfolio of products by leveraging scale, competencies and
Slide 10: Select Highlights of Complementary Product Portfolio
Select Highlights of Complementary Product Portfolio Men’s Health / Urology Orthopedics / Pain Other Specialty 9 ©2014 Endo Pharmaceuticals Inc. All rights reserved.
Auxilium Pharmaceuticals — Merger or Acquisition (October 2014) on 6ix